PT  - JOURNAL ARTICLE
AU  - Zhou, Hengxing
AU  - Lou, Yongfu
AU  - Chen, Lingxiao
AU  - Kang, Yi
AU  - Liu, Lu
AU  - Cai, Zhiwei
AU  - Anderson, David B
AU  - Wang, Wei
AU  - Zhang, Chi
AU  - Wang, Jinghua
AU  - Ning, Guangzhi
AU  - Gao, Yanzheng
AU  - He, Baorong
AU  - Ding, Wenyuan
AU  - Wang, Yisheng
AU  - Mei, Wei
AU  - Song, Yueming
AU  - Zhou, Yue
AU  - Xia, Maosheng
AU  - Wang, Huan
AU  - Zhao, Jie
AU  - Yin, Guoyong
AU  - Zhang, Tao
AU  - Jing, Feng
AU  - Zhu, Rusen
AU  - Meng, Bin
AU  - Duan, Li
AU  - Deng, Zhongliang
AU  - Zhang, Zhongmin
AU  - Wu, Desheng
AU  - Liu, Yajun
AU  - Cai, Zhengdong
AU  - Huang, Lin
AU  - Yin, Zhanhai
AU  - Li, Kainan
AU  - Lu, Shibao
AU  - Cao, Xu
AU  - Feng, Shiqing
TI  - Epidemiological and Clinical Features, Treatment Status, and Economic Burden of Traumatic Spinal Cord Injury in China
AID  - 10.1101/2021.09.27.21264179
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.27.21264179
4099  - http://medrxiv.org/content/early/2021/09/29/2021.09.27.21264179.short
4100  - http://medrxiv.org/content/early/2021/09/29/2021.09.27.21264179.full
AB  - Background China has the largest population of traumatic spinal cord injury (TSCI), but has not yet performed a national-level study on its epidemiological and clinical features, treatment status, and economic burden.Methods A total of 14 754 patients were recruited between January 2013 and December 2018 from 37 hospitals in 11 provinces and municipalities, which represented all geographical divisions of China. The percentage of TSCI in hospitalized patients and the percentage of TSCI in hospitalized patients through the orthopaedic departments were calculated. The treatment status, total and daily costs were collected.Results The percentage of TSCI in hospitalized patients and the percentage of TSCI in hospitalized patients through the orthopaedic departments did not change significantly overall (APC= -0.5%, 95% CI: -3.0 to 2.1 and -1.6%, -4.9 to 1.8, respectively). A total of 10 918 (74.0%) patients received surgery after TSCI. However, only 3.0% of patients underwent surgery received surgery less than 24 hours after injury. A total of 2 084 (14.1%) patients were treated with methylprednisolone sodium succinate/methylprednisolone (MPSS/MP) at a high dose (≥500 mg) and 641 (4.3%) patients receiving it within 8 hours. The total costs for acute TSCI decreased (-4.8%, -6.2 to -3.4), while the daily costs did not change significantly (0.5%, -1.2 to 2.2).Conclusions This study revealed epidemiological and clinical features, treatment status, and economic burden of TSCI that occurred in China from 2013 to 2018.Funding National Key Research and Development Project of Stem Cell and Transformation Research (2019YFA0112100).Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThe trial ID was ChiCTR1800019691Funding StatementNational Key Research and Development Project of Stem Cell and Transformation Research (2019YFA0112100). This funding organization has no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by Medical Research Ethics Committee of Tianjin Medical University General Hospital [IRB2018-154-01] and all participating centresAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableThe data are available from the corresponding author on reasonable request.